Philip Kantoff
Director/Board Member at CONTEXT THERAPEUTICS INC.
Net worth: 4 873 $ as of 30/03/2024
Profile
Philip Wayne Kantoff is the founder of Convergent Therapeutics, Inc. He currently holds multiple positions including Chairman-Global Treatment Science Network at Prostate Cancer Foundation, and Independent Director at ESSA Pharma, Inc., Context Therapeutics LLC, and Context Therapeutics, Inc. In the past, he served as Chairman-Medicine Department at Memorial Sloan Kettering Cancer Center, Director-Lake Center for Genitourinary Oncology at Dana-Farber Cancer Institute, Inc., Medicine Professor at Harvard University, Principal at National Institutes of Health, and Professor Emeritus-Medicine at Harvard Medical School.
He received his graduate degree from Brown University in 1979.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 30/05/2023 | 3,531 ( 0.02% ) | 4 873 $ | 30/03/2024 | |
ESSA PHARMA INC
-.--% | 24/03/2024 | 0 ( -.--% ) | - $ | 30/03/2024 |
Philip Kantoff active positions
| Companies | Position | Start |
|---|---|---|
| CONTEXT THERAPEUTICS INC. | Director/Board Member | 30/11/2018 |
| ESSA PHARMA INC. | Director/Board Member | 12/09/2022 |
Context Therapeutics LLC
 Context Therapeutics LLC Pharmaceuticals: MajorHealth Technology Context Therapeutics LLC develops novel medicines for hormone responsive cancers. The company was founded by Martin Lehr in 2016 and is headquartered in Philadelphia, PA. | Director/Board Member | 30/11/2019 |
| Prostate Cancer Foundation | Corporate Officer/Principal | - |
Convergent Therapeutics, Inc.
 Convergent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Convergent Therapeutics, Inc. is a clinical stage pharmaceutical company located in Cambridge, MA. The company focuses on developing next generation radiopharmaceutical therapies for prostate and other cancers. The company's proprietary technology involves dual-targeted radionuclide therapy (RNT) developed by Dr. Neil Bander, a professor of urologic oncology at Weill Cornell Medicine and licensed to Convergent by Cornell University. The company's lead product candidate, Conv01-?, is a monoclonal antibody conjugated with actinium-225 (225Ac), a radioactive alpha particle emitter, designed to bind to the prostate-specific membrane antigen (PSMA). If FDA-approved, Conv01-? would be the first antibody approved to direct a radioisotope to prostate cancer, and the first drug approved for the use of 225Ac in a cancer treatment. The company was founded by Philip Wayne Kantoff and Neil H. Bander, and Philip Wayne Kantoff has been the CEO since incorporation. | Chief Executive Officer | 30/06/2021 |
Former positions of Philip Kantoff
| Companies | Position | End |
|---|---|---|
Dana-Farber Cancer Institute, Inc.
 Dana-Farber Cancer Institute, Inc. Hospital/Nursing ManagementHealth Services Dana-Farber Cancer Institute, Inc. provides treatment to cancer patients and also researches new cancer diagnostics, treatments, and preventions. The firm's patients receive treatment through its cancer centers operated with Brigham and Women's Hospital, Children's Hospital Boston, Massachusetts General Hospital, and Beth Israel Deaconess Medical Center. The company was founded by Sidney Farber in 1947 and is headquartered in Boston, MA. | Corporate Officer/Principal | 31/12/2014 |
| Harvard Medical School | Corporate Officer/Principal | - |
Memorial Sloan Kettering Cancer Center
 Memorial Sloan Kettering Cancer Center Hospital/Nursing ManagementHealth Services Memorial Sloan-Kettering Cancer Center operates as a private cancer center. It offers cancer care services to adult; and child and teen patients. Its services include risk assessment and screening; diagnosis and treatment; clinical trials; patient and caregiver education; and pediatric clinical trials. The company was founded by John J. Astor and Charlotte Astor in 1884 and is headquartered in New York, NY. | Corporate Officer/Principal | - |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
| ░░░░░░░░ ░░░░░░░░░░ ░░ ░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Training of Philip Kantoff
| Brown University | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| ESSA PHARMA INC. | Health Technology |
| CONTEXT THERAPEUTICS INC. | Health Technology |
| Private companies | 6 |
|---|---|
Dana-Farber Cancer Institute, Inc.
Dana-Farber Cancer Institute, Inc. Hospital/Nursing ManagementHealth Services Dana-Farber Cancer Institute, Inc. provides treatment to cancer patients and also researches new cancer diagnostics, treatments, and preventions. The firm's patients receive treatment through its cancer centers operated with Brigham and Women's Hospital, Children's Hospital Boston, Massachusetts General Hospital, and Beth Israel Deaconess Medical Center. The company was founded by Sidney Farber in 1947 and is headquartered in Boston, MA. | Health Services |
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center Hospital/Nursing ManagementHealth Services Memorial Sloan-Kettering Cancer Center operates as a private cancer center. It offers cancer care services to adult; and child and teen patients. Its services include risk assessment and screening; diagnosis and treatment; clinical trials; patient and caregiver education; and pediatric clinical trials. The company was founded by John J. Astor and Charlotte Astor in 1884 and is headquartered in New York, NY. | Health Services |
National Institutes of Health
 National Institutes of Health General GovernmentGovernment National Institutes Of Health conducts & supports peer-reviewed medical research and science. The firm's scientists & researchers investigate on different ways to prevent diseases as well as the causes, treatments and cures for common and rare diseases. The company was founded in 1887 and is headquartered in Bethesda, MD. | Government |
| Prostate Cancer Foundation | Miscellaneous |
Context Therapeutics LLC
Context Therapeutics LLC Pharmaceuticals: MajorHealth Technology Context Therapeutics LLC develops novel medicines for hormone responsive cancers. The company was founded by Martin Lehr in 2016 and is headquartered in Philadelphia, PA. | Health Technology |
Convergent Therapeutics, Inc.
Convergent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Convergent Therapeutics, Inc. is a clinical stage pharmaceutical company located in Cambridge, MA. The company focuses on developing next generation radiopharmaceutical therapies for prostate and other cancers. The company's proprietary technology involves dual-targeted radionuclide therapy (RNT) developed by Dr. Neil Bander, a professor of urologic oncology at Weill Cornell Medicine and licensed to Convergent by Cornell University. The company's lead product candidate, Conv01-?, is a monoclonal antibody conjugated with actinium-225 (225Ac), a radioactive alpha particle emitter, designed to bind to the prostate-specific membrane antigen (PSMA). If FDA-approved, Conv01-? would be the first antibody approved to direct a radioisotope to prostate cancer, and the first drug approved for the use of 225Ac in a cancer treatment. The company was founded by Philip Wayne Kantoff and Neil H. Bander, and Philip Wayne Kantoff has been the CEO since incorporation. | Health Technology |
- Stock Market
- Insiders
- Philip Kantoff
